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AbstrACt
Objectives We have previously developed and 
validated the Arthritis Research UK Musculoskeletal 
Health Questionnaire (MSK-HQ) for use across 
musculoskeletal care pathways, showing encouraging 
psychometric test results. The objective of this study 
was to determine the responsiveness of MSK-HQ 
following MSK treatments and to determine the 
minimally important change (MIC).
setting We collected data in four cohorts from community 
physiotherapy and secondary-care orthopaedic hip, knee 
and shoulder clinics.
Participants 592 individuals were recruited; 210 
patients treated with physiotherapy for a range of MSK 
conditions in primary care; 150 patients undergoing 
hip replacement, 150 patients undergoing knee 
replacement and 82 undergoing shoulder surgery in 
secondary care.
Outcome measures Preoperative data were collected 
including the MSK-HQ, European Quality of Life-5D 
(EQ-5D) and the OHS, OKS or OSS in each joint-specific 
group. The same scores, together with anchor questions, 
were collected postintervention at 3 months for the 
physiotherapy group and 6 months for all others. Following 
COnsensus-based Standards for the selection of health 
status Measurement INstruments (COSMIN) guidelines, 
responsiveness was assessed using correlation between 
scores and the MIC was calculated for the entire cohort 
using receiver operating characteristic curve analysis.
results The MSK-HQ demonstrated strong correlation 
(R=0.73) with EQ-5D across the entire cohort and 
with each of the joint-specific Oxford scores (hip 
R=0.87, knee R=0.92 and shoulder R=0.77). Moderate 
correlation was seen between MSK-HQ and EQ-5D 
across each individual group (R value range 0.60–
0.68), apart from the hip group where correlation was 
strong (R=0.77). The effect size with MSK-HQ was 
0.93, in the entire cohort, double that measured with 
EQ-5D (0.43). In all subgroups, MSK-HQ measured a 
greater treatment effect compared with EQ-5D. The 
MIC is 5.5 (95% CI 2.7 to 8.3).
Conclusion Our study demonstrates that the MSK-HQ 
questionnaire is responsive to change across a range of 
musculoskeletal conditions, supporting its use as a generic 
MSK measurement instrument.
IntrOduCtIOn
Musculoskeletal (MSK) health problems 
affect one in four of the adult popula-
tion and managing this diverse spectrum 
of conditions is expensive, for instance in 
the NHS accounting for approximately 
£5 billion of spending annually.1 Patients 
with MSK pain usually enter the clinical 
pathway via their primary care doctor 
presenting with a wide range of different 
diagnoses and representing up to 14% 
of all consultations.2 Given the scale of 
the MSK healthcare burden, new ways of 
providing care are developing across all 
healthcare systems. Within the UK, the 
pathway for providing MSK services has 
developed significantly over the last 15 
years.3 Primary care treatment is effective 
strengths and limitations of this study
 ► The Musculoskeletal Health Questionnaire (MSK-HQ) 
has been shown to be responsive across a range of 
musculoskeletal (MSK) conditions.
 ► The MSK-HQ performed well in comparison with 
other quality-of-life-based questionnaires, including 
the European Quality of Life-5D score.
 ► The minimally important change value for the 
MSK-HQ in the general MSK population has been 
calculated.
 ► A limitation of the study is that the MSK-HQ has not 
been tested across all MSK conditions.
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in managing many MSK problems but a significant 
proportion of patients will be referred through an 
intermediate care pathway where more diagnostic tests 
may be undertaken and physiotherapy care provided.4 
A proportion of these patients have symptoms resistant 
to initial therapy and are referred on to hospital-based 
secondary care for assessment by orthopaedic, rheu-
matology or sports medicine doctors.5 These pathways 
have become formally established within the UK with 
the development of integrated MSK clinical assessment 
and treatment services.6 The development of care path-
ways in MSK services has occurred in parallel with the 
drive towards validated outcome-based assessment of 
the care provided and value-based commissioning.7 To 
facilitate this, there has been a requirement to create 
a relevant generic MSK patient-reported outcome 
measure (PROM) that could be used to assess all 
MSK patients as they initially enter and then prog-
ress through the pathway, regardless of diagnosis.8 
This requirement reflects the increasing need across 
all healthcare models to embed the measurement of 
clinical change over time. To achieve this, a responsive 
PROM is required. The European Quality of Life Ques-
tionnaire (EQ-5D-5L) patient measure has been previ-
ously widely used for this role in MSK care, but some 
concerns have been raised regarding its lack of respon-
siveness.9 10 This may reflect the measurement prop-
erties of EQ-5D-5L as a generic healthcare quality of 
life measure rather than a condition or disease-specific 
measure. More specifically, the EQ-5D-5L individual 
items have no musculoskeletal context for patients, 
which is an important characteristic for embedding 
them in a clinical pathway.
To address this need ,the Arthritis Research UK 
Musculoskeletal Health Questionnaire (MSK-HQ) was 
developed.8 This is a generic MSK PROM, designed to 
be used across the full spectrum of MSK conditions. 
The MSK-HQ contains 14 items capturing symptoms 
and functional problems that patients with MSK condi-
tions have identified as important. These include pain 
severity, physical function, work interference, social 
interference, sleep, fatigue, emotional health, phys-
ical activity, independence, understanding, confidence 
to self-manage and overall impact. We have previously 
shown that the MSK-HQ has encouraging psychometric 
test results with high completion rates (94%), excel-
lent test-retest reliability (intraclass correlation coef-
ficient=0.84) and a high level of internal consistency 
(Cronbach’s α=0.88).8 In addition, the score demon-
strates very good convergent validity when measured 
against EQ-5D with a Spearman rank correlation coeffi-
cient of 0.81, respectively.8
The specific aim of this study was to determine the 
responsiveness of the MSK-HQ in measuring clinical 
change as a single generic MSK measure following 
treatment across different MSK pathways. In addition, 
the study aimed to determine the minimally important 
change (MIC) for MSK-HQ.
MethOds
Cohorts
We have developed a series of cohorts of patients to 
validate the MSK-HQ as previously described.8 We used 
follow-up outcome data from the cohorts to deter-
mine the MSK-HQ’s responsiveness and MIC, with data 
collected longitudinally at two time points.
Community physiotherapy cohort
Patients were recruited from community MSK phys-
iotherapy clinics in five UK West Midlands towns 
(Middlewich, Congleton, Wombourne, Cheadle and 
Wolverhampton), where NHS treatment is offered after 
referral by the GP. Patients were invited to take part 
and recruited directly in the clinic having received a 
study information pack. The inclusion criteria were age 
>18 years and referral from a GP for physiotherapy treat-
ment. No further inclusion/exclusion criteria were used, 
creating a study group with a heterogeneous range of 
unspecified MSK problems. Patients consented to fill out 
questionnaires pretreatment and at 3 months after first 
consultation.
Secondary care orthopaedic cohorts (knee, hip, shoulder)
From the Nuffield Orthopaedic Centre in Oxford, we 
recruited separate knee, hip and shoulder cohorts from 
patients who had been listed for surgery. Patients were 
approached in their preassessment clinic appointment 
prior to surgery having received a study information pack. 
Inclusion criteria were age >18 years and patient listed 
for (1) knee replacement surgery, (2) hip replacement 
surgery and (3) shoulder surgery including open and 
arthroscopic procedures (excluding instability surgery). 
Patients consented to fill out a preoperative question-
naire and again at 6-month postsurgery. The shoulder 
cohort had been expanded to 82 compared with the 60 
previously reported.8
Outcome measures
All participants were asked to complete the MSK-HQ and 
EQ-5D-5L (the primary reference measure) as baseline 
and final follow-up as the second time point. The MSK-HQ 
is a 14-item questionnaire assessing pain severity, physical 
function, work interference, social interference, sleep, 
fatigue, emotional health, physical activity, independence, 
understanding, confidence to self-manage and overall 
impact. When reporting the MSK-HQ, all 14 items are 
summed together (responses coded from ‘not at all’=4 to 
‘extremely’=0, except for items 12 and 13, which have the 
response options in the reverse order) providing a range 
from 0 to 56, with higher scores indicating better MSK 
health status.8 The EQ-5D-5L questionnaire is a generic 
quality of life measure, which consists of five domains 
(mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression) with five categorical levels for each 
domain. In addition, the instrument contains a general 
health VAS (0–100, 0=best health) item. EQ-5D-5L can be 
interpreted in the form of an index score or in the form 
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Table 1 The eight a priori hypotheses that were examined
Number Hypotheses Result
1 The correlation between the MSK-
HQ and EQ-5D within the entire 
cohort is moderate (r≥0.50) or above
Accepted
2 The correlation between the 
MSK-HQ and EQ-5D within the 
physiotherapy cohort is moderate 
(r≥0.50) or above
Accepted
3 The correlation between the MSK-
HQ and EQ-5D within the knee 
cohort is moderate (r≥0.50) or above
Accepted
4 The correlation between the MSK-
HQ and EQ-5D within the hip cohort 
is moderate (r≥0.50) or above
Accepted
5 The correlation between the MSK-
HQ and EQ-5D within the shoulder 
cohort is moderate (r≥0.50) or above
Accepted
6 The correlation between the MSK-
HQ and OKS within the knee cohort 
is moderate (r≥0.50) or above
Accepted
7 The correlation between the MSK-
HQ and OHS within the hip cohort is 
moderate (r≥0.50) or above
Accepted
8 The correlation between the MSK-
HQ and OSS within the knee cohort 
is moderate (r≥0.50) or above
Accepted
EQ-5D-5L, The European Quality of Life Questionnaire; MSK-
HQ, Musculoskeletal Healthcare Questionnaire; OHS, Oxford Hip 
Score; OKS, Oxford Knee Score; OSS, Oxford Shoulder Score; r, 
Spearman correlation coefficient.
of 243 unique health states. In this study, the EQ-5D-5L 
utility score was calculated using the UK Crosswalk 
value set, with scores ranging between −0.59 and 1 (full 
health).11 In addition, the Orthopaedic Cohorts filled 
out a joint specific; Oxford Knee Score (OKS), Oxford 
Hip Score (OHS) or Oxford Shoulder Score (OSS) as 
joint-specific reference measures. The OKS, OHS and 
OSS questionnaires follow are PROMs with 12-item 
addressing pain and functional. In each Oxford question-
naire, every item has five answer categories in a Likert 
scale, with items now scored from 0 to 4. The summary 
score range in all scores is 0 (worst) to 48 (best).12–14 The 
EQ-5D-5L, OKS, OHS and OSS are all widely used PROMs 
with and we have previously published a detailed analysis 
of their established measurement properties.15
This was a longitudinal study and in each group the 
same scores were recorded at final follow-up (3 months 
for physiotherapy and 6 months for orthopaedic cohorts) 
corresponding to the normal clinic practice in each clin-
ical setting. The questionnaires are all patient reported 
and were filled out by the patients with no assistance from 
the research or clinical teams.
evaluation of responsiveness and calculation of MIC
For each of the prospectively collected cohorts, we 
compared the baseline and follow-up scores (3 months 
for the physiotherapy cohort and 6 months for ortho-
paedic cohorts). There is no gold standard measurement 
tool in this context and so we could not apply area under 
the curve methodology. Following COnsensus-based 
Standards for the selection of health status Measure-
ment INstruments (COSMIN) guidelines, we therefore 
used the construct approach and we set a priori hypoth-
eses of expected positive associations at the moderate or 
above level between MSK-HQ and the reference measure-
ment tools (EQ-5D-5L, OKS, OHS, OSS) (table 1). To 
test these, we examined the magnitude and direction of 
change, calculating the Spearman correlation coefficients 
(non-parametric data) for comparison of MSK-HQ and 
other measures, within the different groups. The strength 
of the positive or negative correlation coefficients was 
interpreted according to Munro little, if any (0.00–0.25), 
low (0.26–0.49), moderate (0.50–0.69), high (0.70–0.89) 
and very high correlation (0.90–1.00).16 We expected the 
correlations to be positive and to be moderate or above.
We then performed subgroup analysis calculating and 
comparing the standardised effect size (SES—the mean 
change score divided by the SD of the measure at baseline) 
and the standardised response mean (SRM—the mean 
change score divided by the SD of the change scores) for 
the outcome measure used within each cohorts collected.
For the entire cohort, the clinically relevant change 
(improvement or deterioration) was determined by 
calculating the MIC using receiver operating character-
istic (ROC) curve analysis. For the external anchor, we 
used the following transition item from the Outcome and 
Experience Questionnaire to identify change in clinical 
state compared with baseline (Question: ‘How would 
you now rate the problem you recently came to clinic or 
hospital for?’ Response: ‘Much better’, ‘a little better’, 
‘the same’, ‘a little worse’ or ‘much worse’).17 For calcula-
tion of the MIC, the responses were dichotomised using 
two response groups: (1) improvement=a little better and 
(2) no improvement=same.
COsMIn guIdelInes
We followed COSMIN guidelines for evaluation of 
responsiveness and calculation of MIC.18 The percentage 
of missing items is reported. Complete case analyses were 
performed throughout the analyses for the MSK scores, 
with no imputation for missing values. The power calcu-
lation for sample size of the cohorts has been described 
in first publication regarding these study groups based 
on evaluating test-retest properties.8 Using COSMIN 
standards, the sample size for follow-up data was judged 
as very good for the total group, the physiotherapy, hip 
and knee cohorts (seven times number of items or ≥100 
subjects).19 The sample size for the shoulder cohort was 
inadequate.
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Table 2 Demographic characteristics of patients recruited across the four cohorts
Patient characteristics All participants Physiotherapy Hip Knee Shoulder
Number 592 210 150 150 82
Age (years), mean (SD) 56.0 (16.9) 53.3 (15.5) 55.6 (17.2) 65.7 (13.8) 53.0 (16.7)
Female, n (%) 326 (55.1) 112 (53.3) 88 (58.7) 89 (59.3) 37 (45.1)
Male, n (%) 266 (43.5) 98 (46.7) 62 (41.3) 61 (40.7) 45 (54.9)
Table 3 Base line and follow-up outcomes scores for each cohort
Cohort
Surveys for each 
cohort Baseline Follow-up*
Follow-up
response rate
[Lower–upper 
range} Mean SD Mean SD (%)
Total MSK-HQ (0, 56) 28.6 9.6 41.3 11.4 70
(n=592) EQ-5D-5L ( −0.59, 1) 0.5 0.3 0.7 0.2
Physiotherapy MSK-HQ 30.5 9.6 40.0 11.3 63
(n=210) EQ-5D-5L (−0.59, 1) 0.6 0.3 0.7 0.2
Hip MSK-HQ 24.9 8.3 43.0 12.0 71
(n=150) EQ-5D-5L (−0.59, 1) 0.4 0.2 0.7 0.3
OHS (0, 48) 20.4 8.6 37.4 10.0
Knee MSK-HQ 27.5 9.0 40.8 11.5 82
(n=150) EQ-5D-5L (−0.59, 1) 0.5 0.3 0.7 0.2
OKS (0, 48) 20.9 8.8 34.6 10.1
Shoulder MSK-HQ 32.1 10.4 42.9 9.4 44
(n=82) EQ-5D-5L (−0.59, 1) 0.6 0.3 0.7 0.2
OSS (0, 48) 29.6 10.3 37.5 7.4
Missing data for baseline MSK-HQ: all participants n=50 (8.2%), physiotherapy cohort n=5 (2.4%), hip cohort n=4 (2.7%), knee cohort n=22 
(14.7%),shoulder cohort n=2 (2.4%).
*Follow-up time point: physiotherapy cohort=3 months, hip/knee/shoulder cohorts=6 months.
EQ-5D-5L, The European Quality of Life Questionnaire (range −0.59 and 1); MSK-HQ, Musculoskeletal Healthcare Questionnaire; OHS, 
Oxford Hip Score (range 0–48);OKS, Oxford Knee Score (range 0–48); OSS, Oxford Shoulder Score (range 0–48).
statistical analysis
All analyses were conducted in STATA/IC V.14 (StataCorp 
LP, 2015), SPSS V.22 (IBM Corp, 2013) and Statistical soft-
ware-R V.3.2.2 (The R Foundation for Statistics, 2015).
Patient and public involvement
The MSK-HQ questionnaire in a PROM and its develop-
ment has involved patients in each of the following stages: 
development of the research question, development of 
the outcome measures itself and participating in the 
research.
results
demographic data
There were 592 patients in total who consented to partic-
ipate in the four cohort studies (210 physiotherapy 
patients, 150 hip, 150 knee, 82 shoulder). Baseline popu-
lation characteristics for the overall sample and by each 
cohort are summarised in table 2, showing a mean age of 
56 years (SD 16.9) and with a split of 56.5% female and 
43.5% male. As expected, the symptom episode duration 
was much greater in the secondary care cohorts compared 
with the community physiotherapy cohort.
descriptive analysis of baseline and follow-up scores
Table 3 demonstrates that across the entire cohort there 
was an improvement in mean baseline score to follow-up 
score for both MSK-HQ and EQ-5D. A very similar pattern 
was seen for the physiotherapy cohort. In the joint-spe-
cific cohorts, the same trend occurred across all three 
scores used in each setting. The response rate for the 
entire cohort was 70%.
responsiveness
There was a strong correlation between change scores 
for MSK-HQ and non-disease-specific EQ-5D across the 
entire cohort with an R value of 0.73 (table 4). There was 
moderate correlation between the same measures in the 
physiotherapy (0.67), knee (0.67) and shoulder cohorts 
(0.57), with strong correlation in the hip cohort (0.72). 
When comparing change scores between MSK-HQ and 
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Table 4 Correlations in change score between MSK-HQ 
and other reference outcome scores (EQ-5D, OHS, OKS and 
OSS) in the entire group and the cohorts (physiotherapy, hip, 
knee and shoulder)
Instrument Comparator Cohort
Spearman 
correlation
coefficient (r)
MSK-HQ EQ-5D Total 0.73
MSK-HQ EQ-5D Physiotherapy 0.67
Hip 0.77
Knee 0.68
Shoulder 0.60
MSK-HQ OHS Hip 0.87
OKS Knee 0.92
OSS Shoulder 0.77
EQ-5D-5L, The European Quality of Life Questionnaire ; MSK-HQ, 
Musculoskeletal Healthcare Questionnaire; OHS, Oxford Hip Score; 
OKS, Oxford Knee Score; OSS, Oxford Shoulder Score.
Table 5 Effect size and standard response mean for MSK-
HQ and other established outcome score in the four cohorts 
(physiotherapy, hip, knee and shoulder)
Cohort
(number 
responding)
Effect size (95% 
CIs)* SRM (95% CIs)†
Physiotherapy 
(n=147)
MSK-HQ 0.93 (0.66 to 1.20) 0.99 (0.71 to 1.26)
  EQ-5D-5L 0.43 (0.18 to 0.68) 0.46 (0.21 to 0.71)
Knee (n=107) MSK-HQ 1.53 (1.18 to 1.86) 1.05 (0.74 to 1.35)
  OKS 1.52 (1.19 to 1.85) 1.26 (0.95 to 1.57)
  EQ-5D-5L 0.94 (0.65 to 1.23) 0.87 (0.58 to 1.15)
Hip (n=123) MSK-HQ 2.14 (1.73 to 2.53) 1.56 (1.21 to 1.90)
  OHS 1.93 (1.53 to 2.33) 1.59 (1.22 to 1.95)
  EQ-5D-5L 1.21 (0.88 to 1.52) 1.03 (0.72 to 1.34)
Shoulder 
(n=36)
MSK-HQ 1.05 (0.52 to 1.57) 1.08 (0.55 to 1.60)
  OSS 0.73 (0.22 to 1.23) 0.99 (0.45 to 1.51)
  EQ-5D-5L 0.73 (0.24 to 1.20) 0.76 (0.29 to 1.24)
*Using baseline (BL) (SD).
†Using paired differences (SD).
EQ-5D-5L, The European Quality of Life Questionnaire; MSK-HQ, 
Musculoskeletal Healthcare Questionnaire; OHS, Oxford Hip Score; 
OKS, Oxford Knee Score; OSS, Oxford Shoulder Score.
Oxford scores in the joint-specific cohorts, the correla-
tions for OKS (0.93) and OHS (0.82) were particularly 
strong, with moderate correlation seen with the OSS 
(0.61). The correlations meant in all cases the a priori 
hypotheses were accepted (table 1).
Across all cohorts, the MSK-HQ measured a relatively 
large mean effect size for treatment ranging between 2.14 
in the hip cohort and 0.93 in the physiotherapy cohort. 
Within the physiotherapy cohort, greater responsiveness 
was shown with MSK-HQ compared with EQ-5D, with 
over twice the effect size measured at 3 months. In the 
knee cohort, MSK-HQ measured a similar effect size to 
the OKS (1.53 and 1.52, respectively) at 6 months, both 
of which were greater than that calculated using EQ-5D 
(0.94). A similar pattern was seen within the hip cohort. 
Within the shoulder cohort, the pattern was different 
with MSK-HQ measuring a greater effect size than OSS 
and EQ-5D, which delivered similar results across the 
cohort (both 0.73). The findings were supported by the 
calculated standardised response mean values (table 5).
Minimally important change
The MIC for MSK-HQ was 5.5 (95% CI 2.7 to 8.3) based 
on the optimal cut-off value with specificity 0.66 and 
sensitivity 0.65, with area under the ROC curve 0.66 (see 
figure 1).
dIsCussIOn
The results of this study demonstrate that the MSK-HQ 
PROM is responsive to change across patients with a range 
of MSK conditions. When considering change scores 
across the entire cohort, the MSK-HQ performed well 
compared with EQ-5D with a strong correlation between 
the scores. Within the subgroups, the MSK-HQ correlated 
very well with change measured using the OHS, OKS 
and OSS. This was supported by measured effect sizes, 
particularly for OKS and OHS. For the community physio-
therapy group, the correlation with EQ-5D was moderate 
but there was a much larger measured effect size using 
the MSH-HQ. The trend for the new score to measure 
a larger effect size when compared with EQ-5D was seen 
across all the cohorts.
The requirement to integrate PROMs into clinical 
management and outcome-based commissioning in 
primary and intermediate care has expanded.7 The 
MSK-HQ PROM was designed to be applicable across 
MSK conditions and to be meaningful to patients partic-
ularly in the primary and intermediate care setting.8 
Therefore, it is important to reflect on the results of the 
MSK-HQ across the whole mixed cohort and the commu-
nity physiotherapy cohort, which does represent a truly 
mixed population of different MSK conditions. Previous 
work has shown that the MSK-HQ has excellent test-retest 
reliability and strong convergent validity with reference 
standards.8 Results from the entire cohort and the physio-
therapy cohort suggest that the MSK-HQ is responsive to 
change in the general MSK population and is applicable 
to the primary and intermediate care setting. Consid-
ering its use in this setting, we have calculated a single 
MIC value for the MSK-HQ for application across all 
MSK conditions. The MIC value represents the smallest 
change in MSK-HQ score that represents a meaningful 
change in symptoms over time for an individual patient 
within a care pathway, a score that has been calculated 
for many other outcome measures.20 Physiotherapy has 
a very important role to play in the initial non-opera-
tive management of nearly all MSK conditions, and for 
A
U
TH
O
R 
PR
O
O
F
6 Price AJ, et al. BMJ Open 2019;0:e025357. doi:10.1136/bmjopen-2018-025357
Open access 
Figure 1 A graph showing the receiver operating characteristic (ROC) analysis using MSK-HQ and EQ-5D index change 
scores across the entire cohort. AUC, area under the ROC curve; MSK, Musculoskeletal Healthcare Questionnaire.
many years the outcome measure of choice in this clinical 
space has been EQ-5D.21–25 A key vision of the MSK-HQ 
was to fill the current gap for a single broad health status 
measure instead of relying on generic health tools such as 
the EQ-5D-5L, which have been shown to be less sensitive 
to change in MSK populations.9 10 One key requirement 
for the MSK-HQ yet to be tested is whether it is more 
sensitive to change than the EQ-5D-5L. Encouragingly, 
the MSK-HQ performed favourably in comparison to 
EQ-5D in terms of responsiveness to change across the 
cohort.
Despite the MSH-HQ not being joint or condition 
specific, the new score performed well in responsiveness 
when compared with the OHS, OKS and OSS. In partic-
ular, the score appears to measure change in response 
to hip and knee arthroplasty in a similar manner to the 
OKS and OHS with very high measured correlation coef-
ficients and similar effect sizes. The follow-up sample size 
for the shoulder cohort was inadequate, and further work 
is required to determine responsiveness in this group of 
patients.
Our study does have a number of limitations that must 
be addressed. We have not collected any information 
regarding detailed nature of pathology or treatment 
within each cohort, such as stage of disease, time to treat-
ment or detail of reconstructive surgery. Our aim was not 
to explore these issues but only to measure change in the 
MSK-HQ before and after treatment to calculate respon-
siveness across the whole MSK cohort. Our study does 
have missing data from the follow-up cohort. However, 
overall the effective response rate for the entire cohort 
was 70%, which is considered acceptable.26 In calculating 
responsiveness, the sample size for the entire group and 
all individual cohorts, other than shoulder, was very good 
as judged against COSMIN standards. Although the study 
was performed solely in the NHS and the study popula-
tion did not cover all MSK diagnoses, we believe the study 
group is representative and the results generalisable to 
the broad group of MSK patients who exist in all health-
care systems.8
In the our previous publication regarding the produc-
tion of MSK-HQ, we laid out a set of prerequisites that 
should be met for its creation.8 We believe that our 
previous findings together with the results of this study 
show that these conditions have now been met. The score 
has been coproduced with patients and clinicians and 
reflects aspects of health that were meaningful to both. It 
can provide an MSK-specific quantification of a person’s 
MSK health. The score can be used across the MSK 
pathway with different MSK conditions and treatment 
targets. It does demonstrate robust psychometric proper-
ties and it is responsive to change enabling longitudinal 
measurement and the monitoring of changes over time. 
In this study, we have demonstrated that it is applicable 
for use by different MSK health professionals and feasible 
for use in routine clinical practice across the MSK patient 
pathway.
The expansion of MSK intermediate care within the 
NHS has highlighted the need for a generic PROM to 
assist in developing outcome-based commissioning of 
care. The measurement property profile of the MSK-HQ 
PROM appears to support its use in this area, although 
its role is still evolving. Increasingly, there is a common 
clinical pathway for most MSK patients within the NHS. 
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Patients initially seek advice and treatment from their 
GP and if their condition does not settle are referred to 
an MSK intermediate care referral hub, which acts as a 
gateway to secondary care. The pathway is not joint or 
condition specific, so a generic MSK PROM to measure 
clinical change and response to treatment is required for 
the process. The MSK-HQ appears to demonstrate the 
appropriate measurement properties and responsiveness 
to fulfil this role.
COnClusIOn
In summary, the findings from this study show that the 
MSK-HQ appears to be responsive to change across a 
range of MSK conditions, performing favourably when 
compared with EQ-5D.
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